Press coverage about Medivation (NASDAQ:MDVN) has been trending negative on Tuesday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Medivation earned a coverage optimism score of -0.25 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the company’s share price in the immediate future.

TRADEMARK VIOLATION WARNING: This story was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/07/04/medivation-nasdaqmdvn-earns-coverage-optimism-score-of-0-25.html.

Medivation Company Profile

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

Insider Buying and Selling by Quarter for Medivation (NASDAQ:MDVN)

Receive News & Ratings for Medivation Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivation Inc and related companies with MarketBeat.com's FREE daily email newsletter.